Immutep (ASX: IMM) — Company Overview, News & Financial Data
Immutep develops LAG-3 targeted immunotherapies for cancer and autoimmune diseases with clinical-stage product candidates.
Immutep
Immutep is a late clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The company specializes in Lymphocyte Activation Gene-3 therapeutics, leveraging its understanding of immune cell regulation to create targeted biologic candidates. Its pipeline includes soluble LAG-3 proteins designed to activate antigen-presenting cells and enhance T cell responses against solid tumors, including non-small cell lung cancer, head and neck carcinoma, and breast cancer. The company also develops agonist antibodies to selectively suppress autoreactive T cells in autoimmune conditions, while maintaining strategic out-licensing partnerships with global pharmaceutical companies for clinical-stage antagonist antibody assets.
Snapshot
Operations
Products and/or services of Immutep
- Soluble LAG-3 Fusion Protein for Lung Cancer: This lead clinical asset targets antigen-presenting cells to activate innate and adaptive immunity, serving as a late-stage oncology candidate evaluated in global Phase 3 clinical trials alongside anti-PD-1 immunotherapy.
- Soluble LAG-3 Fusion Protein for Head and Neck Cancer: This clinical program evaluates a soluble recombinant fusion protein administered alongside immune checkpoint blockers in late-stage clinical trials to treat patients diagnosed with recurrent or metastatic head and neck squamous cell carcinoma.
- Soluble LAG-3 Fusion Protein for Breast and Solid Tumors: This therapeutic program investigates dose escalation and combination treatments with chemotherapy and targeted agents across clinical trials targeting metastatic breast cancer, soft tissue sarcoma, and multiple solid tumor indications.
- Selective Agonist LAG-3 Antibody for Autoimmune Diseases: This proprietary monoclonal antibody selectively targets and suppresses autoreactive T cells in early clinical development, aiming to control tissue inflammation and treat underlying autoimmune conditions without inducing general immunosuppression.
- Out-Licensed Antagonist LAG-3 Oncology Antibodies: This biopharmaceutical licensing segment partners antagonist monoclonal antibody intellectual property with global pharmaceutical corporations, earning milestone payments and royalties as partners advance combination immunotherapies through clinical evaluation.
- Out-Licensed Autoimmune LAG-3 Programs: This corporate partnership activity licenses targeted lymphocyte-modulating antibody candidates to international pharmaceutical partners, advancing specialized therapeutic assets through clinical trials targeting inflammatory and autoimmune diseases worldwide.
Immutep executive team
- Marc VoigtCEO, MD, CFO, Chief Business Officer & Executive Director
- Deanne MillerCOO, General Counsel & Joint Company Secretary
- Frederic TriebelChief Scientific Officer & Executive Director
- Christian MuellerChief Development Officer
- Stephan WinckelsChief Medical Officer
- Indira NaiduJoint Company Secretary
Latest news about Immutep
Immutep contracts new manufacturing batch following study failure
AustraliaImmutep secures USPTO patent for cancer treatment anew
AustraliaFDA grants Orphan Drug status to Immutep's sarcoma therapy
AustraliaImmutep reaches key milestone in autoimmune disease study
AustraliaImmutep hits 50% enrollment in Phase 3 trial
Australia
Recent announcements
What Immutep (IMM) has told the market, newest first.
- Immutep Regains Compliance with Nasdaq
- Audit and Risk Committee Update
- Final Director's Interest Notice - P Meyers
- Notification of cessation of securities - IMM
- Resignation of Non-Executive Director
- Change of Director's Interest Notice - P Meyers
- Application for quotation of securities - IMM
- Becoming a substantial holder
Key financials
Reported results for Immutep, in AUD.
- Market cap
- 33.9M
- Revenue (TTM)
- 19.9M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.1
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 14.6M | -83.9M | -79.3M | |
| 5M | -126.4M | -61.4M | |
| 3.8M | -88.1M | -42.7M | |
| 3.5M | -44.9M | -39.9M |